Limits...
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B - Ann. Oncol. (2015)

Bottom Line: The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology.Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007).When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923).

View Article: PubMed Central - PubMed

Affiliation: Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.

No MeSH data available.


Related in: MedlinePlus

Impact of (A) response category or (B) PET-status + response category on progression-free survival (overall IRC) for patients with baseline FDG-PET assessment. CR, complete response; NR, not reached; PET, position emission tomography; PR, partial response; SD, stable disease.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4374388&req=5

MDV010F2: Impact of (A) response category or (B) PET-status + response category on progression-free survival (overall IRC) for patients with baseline FDG-PET assessment. CR, complete response; NR, not reached; PET, position emission tomography; PR, partial response; SD, stable disease.

Mentions: Patients who achieved CR/CRu by overall IRC had prolonged PFS (median 25.9 months) compared with other response groups (PR or SD; P = 0.0007; supplementary Table S3, available at Annals of Oncology online, Figure 2). The majority (13/16) of patients who achieved CR/CRu were PET-negative with the median PFS not reached; the three patients who achieved CR/CRu but were PET-positive had a median PFS of 9.2 months. Patients who achieved PR or SD by conventional criteria had similar PFS (P = 0.6427). When stratifying PR/SD patients by PET status, patients who achieved PR/SD with PET-negative disease had a notable trend toward prolonged PFS versus those who remained PET-positive (median 18.2 versus 7.1 months, respectively), although the difference was not significant (P = 0.0923).Figure 2.


Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B - Ann. Oncol. (2015)

Impact of (A) response category or (B) PET-status + response category on progression-free survival (overall IRC) for patients with baseline FDG-PET assessment. CR, complete response; NR, not reached; PET, position emission tomography; PR, partial response; SD, stable disease.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4374388&req=5

MDV010F2: Impact of (A) response category or (B) PET-status + response category on progression-free survival (overall IRC) for patients with baseline FDG-PET assessment. CR, complete response; NR, not reached; PET, position emission tomography; PR, partial response; SD, stable disease.
Mentions: Patients who achieved CR/CRu by overall IRC had prolonged PFS (median 25.9 months) compared with other response groups (PR or SD; P = 0.0007; supplementary Table S3, available at Annals of Oncology online, Figure 2). The majority (13/16) of patients who achieved CR/CRu were PET-negative with the median PFS not reached; the three patients who achieved CR/CRu but were PET-positive had a median PFS of 9.2 months. Patients who achieved PR or SD by conventional criteria had similar PFS (P = 0.6427). When stratifying PR/SD patients by PET status, patients who achieved PR/SD with PET-negative disease had a notable trend toward prolonged PFS versus those who remained PET-positive (median 18.2 versus 7.1 months, respectively), although the difference was not significant (P = 0.0923).Figure 2.

Bottom Line: The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology.Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007).When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923).

View Article: PubMed Central - PubMed

Affiliation: Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.

No MeSH data available.


Related in: MedlinePlus